# Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Source: https://onco.cc/trials/nct04665609/  
OnCo record `nct04665609` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Thermal ablation in Hepatocellular carcinoma, run by Chinese PLA General Hospital, with a status the registry has not verified recently.

## Summary

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC is a phase 3 interventional study registered as NCT04665609 by Chinese PLA General Hospital, with 80 participants planned, started 2021-03-05 and due to reach its primary completion in 2022-12-31. Interventions recorded: Anlotinib and TQB2450 solution, TQB2450 solution. Conditions recorded: Hepatocellular Carcinoma, Thermal Ablation, Anlotinib, PDL-1.

Linked to the technology Thermal ablation because the registry's title names it ("thermal ablation") and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04665609
- Phase: 3
- Setting: Safety and Effectiveness of Thermal Ablation Combined With Anlotinib and TQB2450 Solution for Advanced Hepatocelualr Carcinoma
- Sponsor: Chinese PLA General Hospital
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT04665609: https://clinicaltrials.gov/study/NCT04665609

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Thermal ablation (RFA, microwave, cryo)](https://onco.cc/technologies/thermal-ablation/)

---
JSON: https://onco.cc/api/v1/entities/nct04665609.json